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Abstract
Background Olfactory dysfunction has shown to accompany COVID-19. There are varying data regarding the exact frequency in
the various study population. The outcome of the olfactory impairment is also not clearly defined.
Objective To find the frequency of olfactory impairment and its outcome in hospitalized patients with positive swab test for
COVID-19.
Methods This is a prospective descriptive study of 100 hospitalized COVID-19 patients, randomly sampled, from February to
March 2020. Demographics, comorbidities, and laboratory findings were analyzed according to the olfactory loss or sinonasal
symptoms. The olfactory impairment and sinonasal symptomswere evaluated by 9 Likert scale questions asked from the patients.
Results Ninety-two patients completed the follow-up (means 20.1 (± 7.42) days). Twenty-two (23.91%) patients complained of
olfactory loss and in 6 (6.52%) patients olfactory loss was the first symptom of the disease. The olfactory loss was reported to be
completely resolved in all but one patient. Thirty-nine (42.39%) patients had notable sinonasal symptoms while rhinorrhea was
the first symptom in 3 (3.26%). Fifteen patients (16.3%) had a taste impairment. Patients with sinonasal symptoms had a lower
age (p = 0.01). There was no significant relation between olfactory loss and sinonasal symptoms (p = 0.07).
Conclusions Sudden olfactory dysfunction and sinonasal symptoms have a considerable prevalence in patients with COVID-19.
No significant association was noted between the sinonasal symptoms and the olfactory loss, which may suggest that other
mechanisms beyond upper respiratory tract involvement are responsible for the olfactory loss.
Keywords Olfaction disorders . Pandemics . Smell . Taste
Introduction
Coronavirus disease 2019 (COVID-19) is an official name
applied by the World Health Organization (WHO), referring
to a recently emerged disease that has now become the pan-
demic of the twenty-first century. The responsible virus was
named as “severe acute respiratory syndrome coronavirus 2”
(SARS-CoV- 2). The virus causing COVID −19 is a SARS-
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like coronavirus with a 29,903 bp single-stranded RNA (ss-
RNA) [1].
Human coronaviruses (HCoV)were identified as one of the
main causes of acute upper respiratory tract infections (URTI)
in the 1960s [2]. Later, various coronavirus species, including
HCoV-NL63, associated with acute laryngotracheitis (croup),
were identified [2, 3]. A coronavirus belonging to the 2b β-
coronavirus group was detected in 2002 as the cause of severe
lower respiratory tract infection (LRTI) in China, named as a
severe acute respiratory syndrome (SARS) [4]. In 2012, an-
other coronavirus belonging to the 2c β-coronavirus group
caused a highly pathogenic LRTI in Saudi Arabia, named
Middle East respiratory syndrome (MERS), which became
epidemic mainly in the Middle East [5, 6]. In these newly
emerged groups of coronaviruses, although the main site of
involvement in the lower respiratory tract, mild symptoms of
URTI have been reported in MERS and SARS [7, 8].
Sinonasal symptoms in an URTI are due to generalized
mucosal edema that is also the reason for olfactory loss en-
countered during the acute phase of an URTI [9]. However,
the olfactory loss may also occur following the resolution of
sinonasal symptoms, the entity known as post-viral olfactory
loss [10]. Although there are more than 200 subtypes of vi-
ruses associated with URTI, not all of which have been stud-
ied concerning olfactory loss, influenza or parainfluenza vi-
ruses, rhinovirus, picornavirus, human coronavirus, and
Epstein-Barr virus are among those that have been mentioned
as the cause of post-viral olfactory loss [11–13]. Olfactory loss
has been identified in very limited case reports in SARS,
which was not associated with sinonasal symptoms [14]. It
has been suggested that the virus can infect the brain via the
nasal cavity epithelium and olfactory pathway in animals in-
fected by MERS-CoV and SARS-CoV [15].
Since the outbreak of the COVID-19 in Iran, plenty of
patients with olfactory loss have been reported by the otolar-
yngologists. The objective of this study was to investigate the
frequency of the olfactory impairment and the rate of recov-
ery, together with any accompanying URTI (sinonasal symp-
toms) during the recent COVID-19 pandemic.
Methods
This prospective descriptive study was performed on hospi-
talized patients with COVID-19 from February to
March 2020, randomly sampled from the COVID care wards
of a tertiary referral hospital (Hazrat Rasool Akram Hospital)
in Tehran, Iran. The protocol of the study was approved by the
Institutional Review Board and ethics committee of Iran
University of Medical Sciences (code number 1399.052).
The study protocol was in accordance with the 1964
Helsinki declaration and its later amendments comparable
ethical standards. Written informed consent was obtained
from all participants.
Study participants
One hundred adult patients under the age of 80, having posi-
tive throat swab specimens in the evaluation of reverse
transcriptase-polymerase chain reaction, were enrolled in the
study. Patients with COVID-19 were diagnosed according to
the WHO interim guideline [16, 17]. Patients with well-
known neurodegenerative diseases, including Parkinson’s dis-
ease or dementia, history of olfactory dysfunction, as well as
those with severe respiratory distress or under mechanical
ventilation, were excluded from the study.
Data collection
The demographic characteristics (age and sex), comorbidities,
previous chronic sinonasal disease or related surgery, seasonal
allergy, smoking habits, time of disease onset, and the first
symptom(s) at the onset, and those added later, were asked
from the patients. The oxygen saturation, assessed by a pulse
oximeter, was also recorded. Laboratory results, including
leukocyte and lymphocyte count, c-reactive protein (CRP),
erythrocyte sedimentation rate, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), blood urea nitrogen
(BUN), and creatinine, were recorded from the electronic
medical records of the hospital. Fever was defined as an axil-
lary temperature of ≥ 37.5 °C.
The radiological assessment of all the patients was carried
out using chest computed tomographic (CT) scans. The pa-
tients were interviewed regarding sinonasal symptoms. Seven
prominent symptoms including needing to blow the nose,
sneeze, rhinorrhea, postnasal discharge, thick nasal discharge,
facial pain over sinuses, and nasal congestion/obstruction
were evaluated using 7 Likert scale questions (five-point
scale; 0: no complaint, 5: extreme severe problem). The group
with sinonasal symptoms was defined considering the sum of
the Likert score when the change in each one was higher than
1 (very mild). The olfaction and taste were also evaluated
using 2 Likert scale questions (five-point scale; 0: no change,
5: complete loss). The same questions were applied when the
patients were called for follow-up. The patients were asked to
score according to the most severe symptoms they had since
the disease onset (and not the severity sensed at the time of the
interview). The highest score was adopted for each patient.
The severity of COVID-19 was defined for the patients ac-
cording to the international guidelines for community-
acquired pneumonia [18]. The throat swab specimens of pa-
tients were analyzed using the SARS-CoV-2 nucleic acid de-




Characteristics were summarized as mean ± standard devia-
tion (SD) for quantitative variables and as a percentage for
qualitative variables, respectively. Inter-group comparison of
categorical and quantitative variables was performed with
Fisher’s exact test and t test, respectively. SPSS (version
22.0, IBM Corp., Armonk, NY, USA) was used to analyze
the statistical variables. P values less than 0.05 were set as
statistically significant levels.
Results
One hundred hospitalized patients who had SARS-CoV2 in-
fection were eligible to be included in the study. Ninety-two
patients completed the follow-up and hence were analyzed (3
patients were not interested with follow-up, 2 patients did not
answer the phone after several attempts, one had a wrong
telephone number registered in the medical record, one patient
deceased after admission to another hospital, and one patient
had a cerebrovascular accident a few days after being
discharged from the hospital). The mean follow-up duration
was 20.10 ± 7.42 days, and 71 (77.2%) patients had more than
2-week follow-up.
Clinical, radiological, and laboratory findings
According to the international guidelines for community-
acquired pneumonia, 72 (78.3%) patients had mild and 20
patients (21.7%) had moderate pneumonia. In the patients
with mild pneumonia, the mean leukocyte and lympho-
cyte count were 6095.07 ± 3669/μl and 1066.76 ± 542/μl,
respectively. In the patients with moderate pneumonia, the
mean leukocyte count and lymphocyte count were 5940 ±
2880/μl and 939.17 ± 441/μl, respectively. The mean age
in mild group was 50.75 ± 12.31 while in the moderate
group it was 60.85 ± 13.82 years. There was a significant
difference between the severity of pneumonia and age
(p = 0.002). The severity of pneumonia and mean leuko-
cyte and lymphocyte count had no association with
sinonasal symptoms or olfactory loss. The details of de-
mographic data, comorbidities, and laboratory findings of
the patients are all presented in Table 1. In 95.7% of our
patients, CRP was higher than the normal level, which
was not significantly different in patients with or without
sinonasal symptoms or olfactory loss. The CT chest scans
of patients were compatible with ground-glass opacity in
71.2%, consolidation in 21.9%, and crazy paving pattern
in 6.8%. The mean of oxygen blood saturation was
91.81% ± 4.34.
Sinonasal symptoms
Sinonasal symptoms were found in 39 (42.39%) patients.
Although the most common presenting symptoms were my-
algia and fever, each in more than one-third of the patients,
rhinorrhea was among the first symptom in 3 (3.26%) of the
cases. Considering the severity, 12 patients (13.04%) had
sinonasal symptoms with a Likert score of 4 or more. The
patients’ manifestations, including sinonasal symptoms and
olfaction, are presented in Table 2. Patients with sinonasal
symptoms had a lower age (p = 0.01) patients with diabetes
mellitus had a lesser chance of presenting with sinonasal
symptoms (p = 0.03). However, patients with diabetes
mellitus (DM) were significantly younger (59.86 ± 12.23 vs.
50.77 ± 12.89, p = 0.004). There was no significant difference
in the other demographic data, comorbidities, and laboratory
findings between those who had sinonasal symptoms compar-
ing to others.
Olfactory loss
The olfactory loss was reported by 22 (23.91%) patients, of
whom 6 (6.52%) patients reported it as the first symptom of
their disease. Anosmia was reported by 9 (40.9%) and
hyposmia by 13 (59.1%), respectively. Two patients reported
hyperosmia. Fifteen patients (16.3%) reported simultaneous
taste impairment. The frequency and severity of sinonasal
symptoms and the olfactory and taste impairment (based on
the Likert scale) are shown in Table 3. There was no signifi-
cant difference in the demographic data, comorbidities, and
laboratory findings between those who had olfactory loss
comparing to others. In the 22 patients with olfactory loss,
the median (mean ± SD) time of the onset of olfactory was
3 days (3.41 ± 2.46) after the onset of COVID-19 symptoms.
The olfactory loss lasted for a median of 8 (10.73 ± 8.26) days
and completely resolved in 21 (95.45%) patients (mean
follow-up for 22 patients with olfactory impairment was
20.63 ± 5.95, ranging from 10 to 30 days). One patient with
anosmia remained symptomatic 30 days after the onset of the
symptom. However, he had shown some degree of improve-
ment at that time (Likert score = 2).
Among 22 patients with olfactory loss, 9 patients had no
sinonasal symptoms. Likewise, among 39 patients with
sinonasal symptoms, 26 patients did not have any olfactory
complain. There was no significant relation between olfactory
loss and upper respiratory tract involvement (p = 0.07).
Discussion
The present study followed 92 hospitalized COVID-19 pa-
tients for around 3 weeks after the start of their disease symp-
toms. The olfactory loss was reported by almost 24% of the
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patients. URTI symptoms were present in 42% of the patients
(severe form only in around 13% of the patients), which did
not correlate with the olfactory loss. Patients with sinonasal
symptoms were significantly younger. The same finding was
observed by Krajewska et al. [19]. Until April 3, 2020, there
have been 3,917,366 and 106,220 laboratory-confirmed cases
of COVID-19 globally and in Iran, respectively [20]. There is
accumulating evidence from all around the world, revealing
the association of olfactory loss with the COVID-19 pandem-
ic. The reported frequency of olfactory impairment in recent
peer-reviewed or not peer-reviewed studies varies greatly [21,
22]. This wide range may be due to various factors including
study design (i.e., retrospective [22], prospective [23], online
survey [24, 25] study population, subdivided in hospitalized
patients [21, 22, 26], out-patient setting [27], and mixed [23,
28]; regional differences in population (racial diversity) [23]
and use of olfactory tests and the test being used [21, 28]. For
instance, Giacomelli et al. [26] found that when being asked,
33.9% of hospitalized patients with COVID-19 reported ol-
factory and/or taste disorder. While Mao et al. [22], collecting
the data from medical electronic records, reported 5.1% of the
hospitalized patients had a complaint of hyposmia.
Olfactory clefts are narrow upper parts of nasal cavities
containing olfactory epithelium with olfactory receptor neu-
rons necessary for olfaction [29]. Various pathologies, includ-
ing common viral URTI, can cause prominent mucosal edema
and subsequent obstruction in the middle and the lower parts
of the nasal cavities, hindering the odors to reach the olfactory
cleft [29]. There was no relation between the upper respiratory
tract involvement and olfactory loss in our patients. This may
suggest that the olfactory loss is not due to generalized muco-
sal edema and nasal obstruction, which occurs during a com-
mon upper respiratory infection [9].
Post-viral olfactory dysfunction is the cause of 18% to 42%
of the patients with olfactory loss [30]. Suzuki et al. [31] were
able to detect rhinovirus, coronavirus, parainfluenza virus, and
Epstein-Barr virus in the nasal discharge of patients with post-
viral olfactory dysfunction for the first time. They suggested
that other mechanisms, apart from nasal obstruction, can be
responsible for olfactory loss in this setting [31]. The exact
Table 1 Demographic data, laboratory finding of 92 patients with COVID-19
Sinonasal symptoms Olfactory loss
Characteristic All (n = 92) With (n = 39) Without (n = 53) P value With (n = 22) Without (n = 70) P value
Demographic data
Age, mean (SD), year 52.94 (13.25) 48.97 (8.09) 55.86 (15.46) .01 52.22 (11.70) 53.17 (13.78) .77
Female, sex 30 (32.6) 13 (33.3) 17 (32.1) .89 9 (40.9) 21 (30.0) .64
Past medical history, N (%)
Sinonasal surgery 5 (5.4) 3 (7.7) 2 (3.8) .41 0 5 (7.1) .19
Chronic rhinosinusitis 12 (13.0) 6 (15.4) 6 (11.3) .56 3 (13.6) 9 (12.9) .92
History of allergy 16 (17.4) 9 (23.1) 7 (13.2) .21 3 (13.6) 13 (18.6) .59
Diabetes mellitus 22 (23.9) 5 (12.8) 17 (32.1) .03 6 (27.3) 16 (22.9) .67
Hypertension 21 (22.8) 5 (12.8) 16 (30.2) .05 4 (18.2) 17 (24.3) .55
Heart disease 14 (15.2) 3 (7.7) 11 (20.8) .08 2 (9.1) 12 (17.1) .35
Habitual history, N (%)
Cigarette smoking 13 (14.1) 9 (23.1) 4 (7.5) .07 4 (18.2) 9 (12.9) .72
Water pipe 10 (10.9) 7 (17.9) 3 (5.7) .07 2 (99.1) 8 (11.4) .72
Laboratory tests, N (%)
Leukocytes/μl < 4000/μl 20 (22.5) 8 (20.51) 12 (22.64) .78 5 (22.72) 15 (21.42) .97
Leukocytes/μl > 10,000/μl 10 (11.2) 5 (12.82) 5 (9.43) .62 1 (4.54) 9 (12.85) .25
Lymphocytes < 1500/μl 69 (75) 32 (82.05) 37 (69.81) .33 16 (72.72) 53 (75.71) .63
Platelets 103/μl < 150 40 (43) 17 (43.58) 23 (43.39) .39 10(45.45) 30(42.85) .56
Laboratory tests, mean (SD)
ESR, mm/h 63.32 (29.12) 59.25 (26.44) 66.94 (31.23) .28 62.13(29.36) 63.66 (29.32) .85
AST, U/L 44.33 (19.75) 40.96 (16.36) 46.97 (12.90) .22 38.06 (23.98) 46.17 (18.19) .16
ALT, U/L 38.83 (31.47) 33.51 (25.19) 43.00 (35.41) .22 33.13 (38.05) 40.50 (29.48) .49
Creatinine, mg/dl 1.45 (1.32) 1.28 (.88) 1.59 (1.57) .28 1.52 (1.18) 1.43 (1.37) .78
BUN, mg/dl 16.89 (15.19) 15.48 (14.92) 17.91(15.46) .47 19.55 (19.81) 16.04 (13.49) .37
ESR, first hour erythrocyte sedimentation rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; SD, standard
deviation; N, number
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mechanism of post-viral olfactory loss is not completely un-
derstood. Direct damage of the olfactory pathway by the virus,
viral involvement of the olfactory bulb, and indirect damage
caused by the subsequent inflammation of olfactory neurons
and supporting cells are among the suggested mechanisms (as
was noted in influenza infection) [9, 32]. There was no signif-
icant relationship between sinonasal symptoms and olfactory
loss in our study, which may support this proposed mecha-
nism. However, the post-viral olfactory loss is usually noted a
few weeks after the resolution of sinonasal symptoms, while
our patients reported the olfactory loss during the first weeks
of their disease. There are few studies regarding the recovery
rate of olfactory dysfunction in COVID-19. Lechien et al. [23]
reported a 44.0% short-term (2 weeks) olfaction recovery rate
Table 2 Symptoms of sinonasal infection and olfactory loss in patients with COVID-19
Sinonasal symptoms Olfactory loss
Characteristic All N (%), n = 92 With N (%), n = 39 Without N (%), n = 53 P value With N (%), n = 22 Without N (%), n = 70 P value
Presenting symptoms*
Myalgia 34 (37.0) 12 (30.8) 22 (41.5) .29 4 (18.2) 30 (42.9) .03
Fever 29 (31.5) 12 (30.8) 17 (32.1) .89 5 (22.7) 24 (34.3) .30
Cough 23 (25.0) 11 (28.2) 12 (22.6) .54 5 (22.7) 18 (25.7) .77
Dyspnea 12 (13.0) 1 (2.6) 11 (20.8) .01 3 (13.6) 9 (12.0) .92
Nausea/vomiting 9 (9.8) 4 (10.3) 5 (9.4) .89 1 (4.5) 8 (11.4) .34
Headache 9 (9.8) 4 (10.3) 5 (9.4) .89 3 (13.6) 6 (8.6) .48
Olfactory loss 6 (6.52) 3 (7.69) 3 (5.66) .69 6 (27.27) 0 < .001
Sore throat 4 (4.3) 1 (2.6) 3 (5.7) .47 1 (4.5) 3 (4.3) .95
Rhinorrhea 3 (3.3) 3 (7.7) 0 .04 3 (13.6) 0 .002
Symptoms
Dyspnea 64 (69.6) 27 (69.2) 37 (69.8) .95 15 (68.2) 49 (70.0) .87
Dry cough 58 (63.0) 24 (61.5) 34 (64.2) .64 16 (72.7) 42 (60.0) .51
Myalgia 57 (62.0) 27 (69.2) 30 (56.6) .21 12 (54.5) 45 (64.3) .41
Fever 50 (54.3) 23 (59.0) 27 (50.9) .44 15 (68.2) 35 (50.0) .13
Weakness 23 (25.0) 14 (35.9) 9 (17.0) .03 9 (40.9) 14 (20.0) .04
Nausea 21 (22.8) 9 (23.1) 12 (22.6) .96 7 (31.8) 14 (20.0) .24
Headache 20 (21.7) 8 (20.5) 12 (22.6) .80 7 (31.8) 13 (18.6) .18
Sore throat 16 (17.4) 10 (25.6) 6 (11.3) .07 8 (36.4) 8 (11.4) .01
Productive cough 13 (14.1) 11 (28.2) 2 (3.8) .001 3 (13.6) 10 (14.3) .93
Diarrhea 12 (13) 8 (20.5) 4 (7.5) .06 4 (18.2) 8 (11.4) .41
Rhinorrhea 8 (8.7) 6 (15.4) 2 (3.8) .05 5 (22.7) 3 (4.3) .01
*Some patients presented with more than one symptom at the disease onset
N, number
Table 3 Severity of sinonasal infection symptoms and olfactory loss according to Likert scores
Linkert scores 0 N (%) 1 N (%) 2 N (%) 3 N (%) 4 N (%) 5 N (%)
Need to nasal blow 70 (76.1) 11 (12) 10 (10.9) 1 (1.1) 0 0
Sneeze 69 (75) 16 (17.4) 6 (6.5) 1 (1.1) 0 0
Rhinorrhea 79 (85.9) 6 (6.5) 5 (5.4) 2 (2.2) 0 0
Post nasal drip 56 (60.9) 11 (12) 11 (12) 6 (6.5) 7 (7.6) 1 (1.1)
Thick rhinorrhea 83 (90) 5 (5.4) 2 (2.2) 1 (1.1) 0 1 (1.1)
Facial pain 84 (91.3) 5 (5.4) 1 (1.1) 1 (1.1) 1 (1.1) 0
Nasal obstruction 85 (92.4) 0 2 (2.2) 3 (3.3) 2 (2.2) 0
Smell loss 70 (76.1) 3 (3.3) 2 (2.2) 4 (4.3) 4 (4.3) 9 (9.8)
Taste loss 77 (83.7) 6 (6.5) 1 (1.1) 2 (2.2) 1 (1.1) 5 (5.4)
N, number
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in COVID-19 patients, while Vaira et al. [28] reported 66%
complete recovery of olfactory dysfunction in their COVID-
19 patients when being asked (mean of days from symptom
onset = 19.3). After mean follow-up of 20 days (10–30 days),
95.5% of these patients reported complete improvement of the
olfactory impairment which is quite higher than the recovery
rate of common post-viral olfactory loss [28, 33].
Trotier et al. [29] showed that in some patients with idio-
pathic olfactory loss, the inflammatory obstruction can be
found only in the olfactory clefts, and not in the rest of the
nasal cavities and sinuses. Hoffmann et al. [34] showed that
the SARS-CoV-2 infects cells through interactions between
its spike (S) protein and the ACE2 protein on target cells. This
interaction requires cleavage of the S protein by the cell sur-
face protease TMPRSS. Base on analyzing the RNA-
sequencing datasets, Brann et al. [33] found that both ACE2
and TMPRSS are expressed by olfactory epithelial supporting
cell and stem cells, and not olfactory sensory neurons, per se.
Accordingly, they hypothesized that the infection of these
cells is the cause of olfactory dysfunction in patients with
COVID-19 [34]. We know that the infected cells secret pro-
inflammatory cytokines and chemokines, resulting in an in-
flux of inflammatory cells [9]. This reaction can also lead to
localized mucosal edema in the narrow olfactory cleft, hinder-
ing the odors pass to the olfactory mucosa (Fig. 1) [35]. This
mechanism can also affect the neurons as bystanders.
However, the neuroinvasiveness of some coronaviruses, in-
cluding SARS-CoV, has demonstrated in both mice and
humans [36]. Accordingly, there are imaging studies of the
brain by MRI, showing a transient increase in volume or
hyperintensity of the olfactory bulb and the brain regions that
are associated with olfaction [37, 38]. It seems that more path-
ologic investigations on the involved nasal mucosa or cadav-
eric brain specimens are needed to find out the exact respon-
sible mechanisms.
Fever has announced as a main symptom of COVID 19,
with a prevalence ranging from 38 to 95.8% that may be due
to the various factors including severity of the disease [22, 39,
40]. The prevalence of fever in Mao et al. [22] study was 61%
while Lechien et al. [23] reported in less than 50% of their
patients. In our patients, fever as a presenting symptom report-
ed by 31.5% of the patients, while it was detected in 54.3% of
the patients during the hospitalization period.
SARS-CoV-2 showed great potential for dissemination be-
came a pandemic during 2.5 months [20]. Although it may be
related to the structure of the virus per se, one explanation
could be the shedding and spreading of the virus by the infect-
ed people with very mild symptoms, similar to those of an
URTI, which could be quite misleading. These patients with
subtle symptoms may unintentionally breach the quarantine
rules. Hence, those who have olfactory loss without any
sinonasal symptoms need to be considered as probable cases
of COVID-19 during the pandemic [21, 23]. This may be of
great importance in controlling the spreading of the COVID-
19. Although we designed a prospective study, data about the
presenting symptoms was collected retrospectively. In this
study, the olfaction and sinonasal symptoms were evaluated
only in patients with COVID-19 that were able to answer the
questionnaire and were hospitalized. Therefore, the reported
frequency may not exactly be the same in milder or very
severe forms of COVID-19. The other limitation is that the
patients were not evaluated with a standard olfactory test; this
was due to the condition of patients with dyspnea and the
preventive protocols that limited unnecessary contacts of per-
sons and instruments during the pandemic. The correlation
between olfactory loss and sinonasal symptoms may need to
be evaluated in larger studies.
Conclusion
Sudden temporary olfactory loss and URTI symptoms have a
considerable prevalence in patients with COVID-19 and need
to be considered as the symptoms of this infection. There was,
however, no association between URTI symptoms and the
prevalence of olfactory loss in these patients, emphasizing that
the pathology may not be the generalized mucosal swelling
that happens during an URTI with common coronaviruses.
The pathophysiology, natural course, prognosis, and
Fig. 1 A non-enhanced coronal
paranasal CT scan of 36-year-old
lady presented only with sudden
anosmia and headache showing
obstruction of olfactory cleft by
kissing mucosal swelling B.
Chest CT scan of the same pa-
tient, after showing COVID-19
symptoms. The sense of smell
was recovered after 8 days of
onset
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therapeutic strategies of olfactory loss caused by SARS-CoV-
2 deserve further investigation.
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